The drug aims to provide new evidence to help diagnose MS and evaluate the scope of damage inflicted on the central nervous system.
Researchers from Cleveland-based Case Western Reserve University developed the drug, which will be tested in healthy volunteers at Cleveland Clinic Mellen Center for Multiple Sclerosis.
Administered through an IV before a PET scan, Myeliviz targets and binds to myelin, the casing surrounding nerves affected by MS.
The National Institutes of Health provided a $1.7 million grant to make the trial possible.
More articles on biologics:
Dr. Fred Naraghi: Cervical disc replacement, spinal fusion will continue to be dominant procedures
$186M in Q4 sales delivered by Novartis gene therapy for spinal muscular atrophy
HSS opens 1st Florida hospital, 2nd new facility in 1 week
